Biopharmaceutical company Suven Life Sciences Ltd. announced that it had secured four products patents - one each from Japan (4886522), Australia (2008315309), Europe (2200980) and Eurasia (16015) corresponding to the New Chemical Entities or NCEs for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2024 and 2027.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, the company has a total of five granted patents from Japan, 14 from Australia, 12 from Europe and ten granted patents from Eurasia.
CEO Venkat Jasti said, 'We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally."
At the BSE, Suven Life Science shares are currently trading at Rs.15.10, up 1.68 percent from the previous close.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org